Form4insider filings, from the source

Company · CIK 0000791908 · SIC 2834 — Pharmaceutical Preparations

XOMA Royalty Corp · XOMA

Insider activity reported against this company. All insider holders · Files at: RZLT. On EDGAR ↗

1M3M6M1Y2YAll datashares as filed — not split-adjusted
Open-market activity at this companybuys $3.9M · 8sales $24.5M · 38net −$20.6M
$10k$10k$1M$1M$100M$100MbuyssalesJan 2015Aug 2015Apr 2016Dec 2016Aug 2017Apr 2018Dec 2018

Reported at this company — common stock

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Apr 6, 2015 DMForm 4 →Apr 7, 7:20 pm EDTFred KurlandCFO & VP Finance65,213$3.61$127,25175,461— plan?
Mar 31, 2015 JForm 5 →Feb 16, 2016, 5:36 pm ESTJames R NealOther15,517$1.65$25,61113,192— plan?
Mar 31, 2015 JForm 5 →Feb 16, 2016, 5:33 pm ESTPaul D RubinSr. VP Clinical Dev. & CMO8,573$1.88$16,15813,422— plan?
Mar 23, 2015 SForm 4 →Mar 23, 6:35 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO32,742$3.94$128,879119,467−21.5% plan?
Mar 18, 2015 DMForm 4 →Mar 20, 7:30 pm EDTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director18,166$4.01$34,755116,120— plan?
Mar 18, 2015 DMForm 4 →Mar 20, 7:30 pm EDTThomas KleinChief Commercial Officer133,704$4.01$212,705185,680— plan?
Mar 18, 2015 DMForm 4 →Mar 20, 7:30 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO50,881$4.01$82,356152,209— plan?
Mar 18, 2015 DForm 4 →Mar 20, 7:30 pm EDTJames R NealOther9,019$4.01$36,171184,469— plan?
Mar 18, 2015 DMForm 4 →Mar 20, 7:30 pm EDTFred KurlandCFO & VP Finance20,038$4.01$36,74880,798— plan?
Mar 18, 2015 DMForm 4 →Mar 20, 7:30 pm EDTJohn VarianCEO, Director81,784$4.01$179,979552,414— plan?
Mar 16, 2015 SForm 4 →Mar 17, 6:52 pm EDTJohn VarianCEO, Director10,000$3.72$37,223560,384−1.75% plan?
Mar 16, 2015 MForm 4 →Mar 17, 6:52 pm EDTJohn VarianCEO, Director10,000$1.24$12,400570,384— plan?
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTJohn VarianCEO, Director193,200——560,384— plan?
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTThomas KleinChief Commercial Officer64,900——158,050— plan?
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTFred KurlandCFO & VP Finance10,000——79,086— plan?
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTJames R NealOther52,500——193,488— plan?
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director38,940——115,286— plan?
Feb 26, 2015 AForm 4 →Mar 2, 7:41 pm ESTPaul D RubinSr. VP Clinical Dev. & CMO64,900——142,398— plan?
Feb 17, 2015 SForm 4 →Feb 19, 6:09 pm ESTJohn VarianCEO, Director10,000$3.52$35,192367,184−2.65% plan?
Feb 17, 2015 MForm 4 →Feb 19, 6:09 pm ESTJohn VarianCEO, Director10,000$1.24$12,400377,184— plan?
Feb 3, 2015 GForm 4 →Feb 4, 5:36 pm ESTFred KurlandCFO & VP Finance16,000——69,086— plan?
Feb 2, 2015 SForm 4 →Feb 3, 1:38 pm ESTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director5,000$3.52$17,62276,346−6.15% plan?
Jan 15, 2015 SForm 4 →Jan 16, 5:22 pm ESTJohn VarianCEO, Director10,000$3.46$34,582367,184−2.65% plan?
Jan 15, 2015 MForm 4 →Jan 16, 5:22 pm ESTJohn VarianCEO, Director10,000$1.24$12,400377,184— plan?
Jan 2, 2015 SForm 4 →Jan 6, 8:31 pm ESTBAKER BROS. ADVISORS LP +6Director, 10% Owner2,215,400$3.81$8,437,818345,074−86.5% plan?
Jan 2, 2015 SForm 4 →Jan 5, 5:32 pm ESTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director5,000$3.55$17,75681,346−5.79% plan?
Dec 31, 2014 JForm 5 →Feb 17, 2015, 6:15 pm ESTFred KurlandCFO & VP Finance3,001$3.83$11,49822,137— plan?
Dec 31, 2014 JForm 5 →Feb 17, 2015, 6:15 pm ESTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director3,001$3.83$11,49825,080— plan?
Dec 31, 2014 JForm 5 →Feb 17, 2015, 6:15 pm ESTJohn VarianCEO, Director3,001$3.83$11,49818,538— plan?
Dec 31, 2014 JForm 5 →Feb 17, 2015, 6:15 pm ESTThomas KleinChief Commercial Officer3,001$3.83$11,4984,660— plan?
Mar 31, 2014 JForm 5 →Feb 17, 2015, 6:15 pm ESTJames R NealOther6,229$4.07$25,3444,471— plan?
Dec 31, 2013 JForm 5 →Feb 17, 2015, 6:14 pm ESTPaul D RubinSr. VP Clinical Dev. & CMO4,579$4.29$19,6566,881— plan?

Reported at this company — derivatives (options, RSUs, warrants)

TradeReported (ET)InsiderSharesAvg priceTotalOwned afterΔ stakeFlags
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTMaricel Perea MontanoChief Legal Officer48,390——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTJoseph M LimberDirector74,500——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTBarbara KosaczDirector69,125——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTJack L WyszomierskiDirector54,801——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTOwen HughesChief Executive Officer, Director423,959——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTNatasha HerndayDirector43,196——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTBradley SitkoChief Investment Officer614,600——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTMatthew D PerryDirector59,657——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTJeffrey TrigilioChief Financial Officer152,924——0—
Jul 14, 2026 DForm 4 →Jul 14, 9:45 pm EDTHeather L FranklinDirector47,008——0—
Feb 13, 2019 AForm 4 →Feb 15, 5:01 pm ESTDeepshikha DattaChief Business Officer50,000——50,000—
Feb 13, 2019 AForm 4 →Feb 15, 5:01 pm ESTThomas M. BurnsSVP, Finance & CFO23,000——23,000—
Feb 13, 2019 AForm 4 →Feb 15, 5:00 pm ESTJames R NealCEO, Director60,000——60,000—
Jan 1, 2019 AForm 4 →Jan 3, 6:50 pm ESTBarbara KosaczDirector19,979——19,979—
Dec 20, 2018 XForm 4 →Dec 21, 6:24 pm ESTJames R NealCEO, Director678——0—
Dec 20, 2018 XForm 4 →Dec 21, 6:22 pm ESTW Denman Van NessDirector800——0—
Dec 14, 2018 XForm 4 →Dec 19, 9:26 pm ESTBVF PARTNERS L P/IL +610% Owner1,823$13,000.00$16,286,036597— late
Nov 15, 2018 MForm 4 →Nov 16, 4:31 pm ESTW Denman Van NessDirector7,693——0—
Jul 19, 2018 AForm 4 →Jul 23, 5:56 pm EDTDeepshikha DattaChief Business Officer24,000——24,000—
May 17, 2018 AForm 4 →May 21, 9:16 pm EDTJoseph M LimberDirector5,052——5,052—
May 17, 2018 AForm 4 →May 21, 9:16 pm EDTW Denman Van NessDirector5,052——5,052—
May 17, 2018 AForm 4 →May 21, 9:15 pm EDTJack L WyszomierskiDirector5,052——5,052—
May 17, 2018 AForm 4 →May 21, 8:53 pm EDTMatthew D PerryDirector5,052——5,052—
Apr 26, 2018 MForm 4 →Apr 27, 5:44 pm EDTThomas M. BurnsSVP, Finance & CFO11,000——24,000—
Apr 26, 2018 MForm 4 →Apr 27, 5:44 pm EDTJames R NealCEO, Director24,000——76,000—
Mar 27, 2018 AForm 4 →Mar 29, 5:11 pm EDTDeepshikha DattaChief Business Officer80,000——80,000—
Feb 14, 2018 AForm 4 →Feb 16, 5:28 pm ESTJames R NealCEO, Director30,000——30,000—
Feb 14, 2018 AForm 4 →Feb 16, 5:28 pm ESTThomas M. BurnsSVP, Finance & CFO25,000——25,000—
Nov 13, 2017 MForm 4 →Nov 15, 8:03 pm ESTJames R NealCEO, Director46,296——266,204—
Nov 13, 2017 MForm 4 →Nov 15, 8:03 pm ESTThomas M. BurnsSVP, Finance & CFO22,222——77,778—
Sep 15, 2017 AForm 4 →Feb 28, 2018, 6:26 pm ESTJoseph M LimberDirector2,366——2,366— late
Sep 15, 2017 AForm 4 →Feb 28, 2018, 6:23 pm ESTJack L WyszomierskiDirector2,366——2,366— late
Sep 15, 2017 AForm 4 →Feb 28, 2018, 6:23 pm ESTW Denman Van NessDirector2,366——2,366— late
Mar 2, 2017 AForm 4 →Mar 7, 7:47 pm ESTMatthew D PerryDirector15,222——15,222— late
Feb 10, 2017 AForm 4 →May 22, 6:48 pm EDTJack L WyszomierskiDirector8,000——8,000— late
Feb 10, 2017 AForm 4 →May 22, 6:45 pm EDTTimothy P WalbertDirector8,000——8,000— late
Feb 10, 2017 AForm 4 →May 22, 6:43 pm EDTJohn VarianDirector8,000——8,000— late
Feb 10, 2017 AForm 4 →May 22, 6:41 pm EDTJoseph M LimberDirector8,000——8,000— late
Feb 10, 2017 AForm 4 →May 22, 6:38 pm EDTPeter Barton HuttDirector8,000——8,000— late
Feb 10, 2017 AForm 4 →May 22, 6:37 pm EDTW Denman Van NessDirector8,000——8,000— late
Feb 10, 2017 AForm 4 →May 22, 6:34 pm EDTThomas M. BurnsVP, Finance & CFO100,000——100,000— late
Feb 10, 2017 AForm 4 →May 22, 6:27 pm EDTJames R NealCEO, Director312,500——312,500— late
Dec 22, 2016 AForm 4 →Dec 23, 6:24 pm ESTThomas M. BurnsVP, Finance & Chief Financial35,000——35,000—
Dec 22, 2016 AForm 4 →Dec 23, 6:07 pm ESTJames R NealVP Business Development100,000——100,000—
Jul 21, 2016 AForm 4 →Aug 2, 7:38 pm EDTTimothy P WalbertDirector60,532——60,532— late
Jul 21, 2016 AForm 4 →Aug 2, 7:34 pm EDTJack L WyszomierskiDirector60,532——60,532— late
Jul 21, 2016 AForm 4 →Aug 2, 7:27 pm EDTW Denman Van NessDirector60,532——60,532— late
Jul 21, 2016 AForm 4 →Aug 2, 7:22 pm EDTW Denman Van NessDirector60,532——60,532— late
Jul 21, 2016 AForm 4 →Aug 2, 7:14 pm EDTJoseph M LimberDirector60,532——60,532— late
Jul 21, 2016 AForm 4 →Aug 2, 7:08 pm EDTPeter Barton HuttDirector121,064——121,064— late
May 28, 2016 MForm 4 →May 31, 7:32 pm EDTJack L WyszomierskiDirector2,800——0—
May 28, 2016 MForm 4 →May 31, 7:28 pm EDTTimothy P WalbertDirector2,800——0—
May 28, 2016 MForm 4 →May 31, 7:25 pm EDTW Denman Van NessDirector3,150——0—
May 28, 2016 MForm 4 →May 31, 7:21 pm EDTJoseph M LimberDirector2,800——0—
Mar 18, 2016 MForm 4 →Mar 22, 9:01 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO12,141——0—
Mar 18, 2016 MForm 4 →Mar 22, 8:58 pm EDTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director9,500——0—
Mar 18, 2016 MForm 4 →Mar 22, 8:55 pm EDTJohn VarianCEO, Director36,907——0—
Dec 12, 2015 MForm 4 →Dec 15, 4:37 pm ESTJoseph M LimberDirector5,600——0—
Aug 14, 2015 MForm 4 →Aug 18, 9:24 pm EDTJohn VarianCEO, Director94,573——195,239—
Aug 14, 2015 MForm 4 →Aug 18, 9:20 pm EDTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director16,264——38,917—
Aug 14, 2015 MForm 4 →Aug 18, 8:24 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO26,748——0—
Jul 15, 2015 MForm 4 →Jul 17, 6:03 pm EDTJohn VarianCEO, Director10,000$1.24$12,40070,392—
Jul 15, 2015 MForm 4 →Jul 17, 6:02 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO5,000$3.04$15,20027,040—
Jul 9, 2015 MForm 4 →Jul 10, 6:57 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO33,400$3.04$101,53632,040—
Jun 15, 2015 MForm 4 →Jun 17, 3:41 pm EDTJohn VarianCEO, Director10,000$1.24$12,40080,392—
May 28, 2015 MForm 4 →Jun 1, 6:24 pm EDTWilliam K Bowes Jr.Director5,600——2,800—
May 28, 2015 MForm 4 →Jun 1, 6:24 pm EDTW Denman Van NessDirector6,300——0—
May 28, 2015 MForm 4 →Jun 1, 6:24 pm EDTJoseph M LimberDirector2,800——2,800—
May 28, 2015 MForm 4 →Jun 1, 6:24 pm EDTTimothy P WalbertDirector5,600——0—
May 28, 2015 MForm 4 →Jun 1, 6:24 pm EDTJack L WyszomierskiDirector5,600——0—
May 28, 2015 MForm 4 →Jun 1, 6:24 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO4,666——0—
May 21, 2015 AForm 4 →May 22, 6:53 pm EDTWilliam K Bowes Jr.Director36,873$3.39$124,99936,873—
May 21, 2015 AForm 4 →May 22, 6:53 pm EDTPeter Barton HuttDirector73,746$3.39$249,99973,746—
May 21, 2015 AForm 4 →May 22, 6:53 pm EDTJoseph M LimberDirector36,873$3.39$124,99936,873—
May 21, 2015 AForm 4 →May 22, 6:52 pm EDTW Denman Van NessDirector36,873$3.39$124,99936,873—
May 21, 2015 AForm 4 →May 22, 6:52 pm EDTTimothy P WalbertDirector36,873$3.39$124,99936,873—
May 21, 2015 AForm 4 →May 22, 6:52 pm EDTJack L WyszomierskiDirector36,873$3.39$124,99936,873—
May 15, 2015 MForm 4 →May 19, 6:08 pm EDTJohn VarianCEO, Director10,000$1.24$12,40090,392—
Apr 15, 2015 MForm 4 →Apr 15, 6:50 pm EDTJohn VarianCEO, Director10,000$1.24$12,400100,392—
Apr 6, 2015 MForm 4 →Apr 7, 7:20 pm EDTFred KurlandCFO & VP Finance29,938——0—
Mar 18, 2015 MForm 4 →Mar 20, 7:30 pm EDTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director9,500——9,500—
Mar 18, 2015 MForm 4 →Mar 20, 7:30 pm EDTThomas KleinChief Commercial Officer80,667——80,666—
Mar 18, 2015 MForm 4 →Mar 20, 7:30 pm EDTPaul D RubinSr. VP Clinical Dev. & CMO30,346——0—
Mar 18, 2015 MForm 4 →Mar 20, 7:30 pm EDTFred KurlandCFO & VP Finance10,875——21,750—
Mar 18, 2015 MForm 4 →Mar 20, 7:30 pm EDTJohn VarianCEO, Director36,907——36,907—
Mar 16, 2015 MForm 4 →Mar 17, 6:52 pm EDTJohn VarianCEO, Director10,000$1.24$12,400110,392—
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTJohn VarianCEO, Director266,800$3.83$1,021,844266,800—
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTThomas KleinChief Commercial Officer86,910$3.83$332,86586,910—
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTJames R NealOther72,500$3.83$277,67572,500—
Feb 26, 2015 AForm 4 →Mar 2, 7:42 pm ESTPatrick J Scannon M.D. Ph.D.Exec. VP & CSO, Director52,146$3.83$199,71952,146—
Feb 26, 2015 AForm 4 →Mar 2, 7:41 pm ESTPaul D RubinSr. VP Clinical Dev. & CMO86,910$3.83$332,86586,910—
Feb 17, 2015 MForm 4 →Feb 19, 6:09 pm ESTJohn VarianCEO, Director10,000$1.24$12,400120,392—
Jan 15, 2015 MForm 4 →Jan 16, 5:22 pm ESTJohn VarianCEO, Director10,000$1.24$12,400130,392—

Filed by this entity as an insider elsewhere — common stock

No reported common-stock activity in this period.

Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)

No reported derivative activity in this period.